Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ambrose

Showing results (181-190 of 250) with videos related to

Pageof 25
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2004
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitisPaul G Ambrose, Jack B Anon, Joel S Owen, et al.
Journal of Orthopaedic Trauma|September 1, 2015
Do Safe Radiographic Sacral Screw Pathways Exist in a Pediatric Patient Population and Do They Change With Age?Matthew Burn, Joshua L Gary, Michael Holzman, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an <i>In Vitro</i> Infection ModelBrian D VanScoy, David Tenero, Simon Turner, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2021
Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber <i>In Vitro</i> Infection Model SystemsBrian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2016
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection ModelsCatharine C Bulik, Ólanrewaju O Okusanya, Elizabeth A Lakota, et al.
Diagnostic Microbiology and Infectious Disease|March 4, 2008
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitisPaul G Ambrose, Jack B Anon, Sujata M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|August 26, 2006
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic modelPatrick F Smith, Brian Tsuji, Brent M Booker, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical StudiesMichael Trang, Julie D Seroogy, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber <i>In Vitro</i> Infection ModelBrian D VanScoy, Nicole E Scangarella-Oman, Steven Fikes, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 16, 2018
Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedsideCatharine C Bulik, Justin C Bader, Li Zhang, et al.
Pageof 25

Showing results (181-190 of 250) with videos related to

Sort By:
Pageof 25
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2004
Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitisPaul G Ambrose, Jack B Anon, Joel S Owen, et al.
Journal of Orthopaedic Trauma|September 1, 2015
Do Safe Radiographic Sacral Screw Pathways Exist in a Pediatric Patient Population and Do They Change With Age?Matthew Burn, Joshua L Gary, Michael Holzman, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an <i>In Vitro</i> Infection ModelBrian D VanScoy, David Tenero, Simon Turner, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2021
Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber <i>In Vitro</i> Infection Model SystemsBrian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2016
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection ModelsCatharine C Bulik, Ólanrewaju O Okusanya, Elizabeth A Lakota, et al.
Diagnostic Microbiology and Infectious Disease|March 4, 2008
Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitisPaul G Ambrose, Jack B Anon, Sujata M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|August 26, 2006
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic modelPatrick F Smith, Brian Tsuji, Brent M Booker, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2019
Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical StudiesMichael Trang, Julie D Seroogy, Scott A Van Wart, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber <i>In Vitro</i> Infection ModelBrian D VanScoy, Nicole E Scangarella-Oman, Steven Fikes, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 16, 2018
Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedsideCatharine C Bulik, Justin C Bader, Li Zhang, et al.
Pageof 25